Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Next Previous
X
Search
Trial Profile

Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RASTS

    • Most Recent Events

    • 01 Dec 2021 Primary endpoint (Baseline to Month 3 Change in Total Power Doppler Synovitis Score of 34 Joints (Range 0 - 102) [ Time Frame: Baseline, 3 Month ]) has been met, as per results published in the Clinical Rheumatology.
    • 01 Dec 2021 Results assessing to determine if baseline or 4-week PDUS changes in rheumatoid arthritis patients started on intravenous tocilizumab can predict 12-week and/or 24-week changes in disease activity and identify which patients may need to titrate TCZ dosage from 4 mg/kg to 8 mg/kg, published in the Clinical Rheumatology.
    • 23 May 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top